Publications

Lawrence Kane

Murter B, Kane LP. Control of T lymphocyte fate decisions by PI3K signaling. F1000Res. 2020;9 doi: 10.12688/f1000research.26928.1. PubMed PMID: 33024547; PMCID: PMC7520711.
Uche UU, Piccirillo AR, Kataoka S, Grebinoski SJ, D'Cruz LM, Kane LP. PIK3IP1/TrIP restricts activation of T cells through inhibition of PI3K/Akt. J Exp Med. 2018 Dec 3;215(12):3165-3179. doi: 10.1084/jem.20172018. PubMed PMID: 30429249; PMCID: PMC6279406.
Tilstra JS, Avery L, Menk AV, Gordon RA, Smita S, Kane LP, Chikina M, Delgoffe GM, Shlomchik MJ. Kidney-infiltrating T cells in murine lupus nephritis are metabolically and functionally exhausted. J Clin Invest. 2018 Nov 1;128(11):4884-4897. doi: 10.1172/JCI120859. PubMed PMID: 30130253; PMCID: PMC6205402.
Corredera E, Phong BL, Moore JA, Kane LP, Lee SE. TIM-3-Expressing Mast Cells Are Present in Chronic Rhinosinusitis with Nasal Polyps. Otolaryngol Head Neck Surg. 2018 Sep;159(3):581-586. doi: 10.1177/0194599818774560. PubMed PMID: 29759032.
Liu Z, McMichael EL, Shayan G, Li J, Chen K, Srivastava R, Kane LP, Lu B, Ferris RL. Novel Effector Phenotype of Tim-3+ Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients. Clin Cancer Res. 2018 Sep 15;24(18):4529-4538. doi: 10.1158/1078-0432.CCR-17-1350. PubMed PMID: 29712685; PMCID: PMC6139056.
Banerjee H, Kane LP. Immune regulation by Tim-3. F1000Res. 2018;7316. doi: 10.12688/f1000research.13446.1. PubMed PMID: 29560265; PMCID: PMC5854983.
Avery L, Filderman J, Szymczak-Workman AL, Kane LP. Tim-3 co-stimulation promotes short-lived effector T cells, restricts memory precursors, and is dispensable for T cell exhaustion. Proc Natl Acad Sci U S A. 2018 Mar 6;115(10):2455-2460. doi: 10.1073/pnas.1712107115. PubMed PMID: 29463725; PMCID: PMC5877951.
Cruz JA, Childs EE, Amatya N, Garg AV, Beyaert R, Kane LP, Aneskievich BJ, Ma A, Gaffen SL. Interleukin-17 signaling triggers degradation of the constitutive NF-κB inhibitor ABIN-1. Immunohorizons. 2017 Sep;1(7):133-141. doi: 10.4049/immunohorizons.1700035. PubMed PMID: 30761389; PMCID: PMC6370333.
Jie HB, Srivastava RM, Argiris A, Bauman JE, Kane LP, Ferris RL. Increased PD-1+ and TIM-3+ TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients. Cancer Immunol Res. 2017 May;5(5):408-416. doi: 10.1158/2326-6066.CIR-16-0333. PubMed PMID: 28408386; PMCID: PMC5497750.
Du W, Yang M, Turner A, Xu C, Ferris RL, Huang J, Kane LP, Lu B. TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action. Int J Mol Sci. 2017 Mar 16;18(3): doi: 10.3390/ijms18030645. PubMed PMID: 28300768; PMCID: PMC5372657.
Shayan G, Srivastava R, Li J, Schmitt N, Kane LP, Ferris RL. Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer. Oncoimmunology. 2017;6(1):e1261779. doi: 10.1080/2162402X.2016.1261779. PubMed PMID: 28197389; PMCID: PMC5283618.
Montecalvo A, Watkins SC, Orange J, Kane LP. Inducible turnover of optineurin regulates T cell activation. Mol Immunol. 2017 May;859-17. doi: 10.1016/j.molimm.2017.01.027. PubMed PMID: 28192730; PMCID: PMC5385146.
Phong B, Avery L, Menk AV, Delgoffe GM, Kane LP. Cutting Edge: Murine Mast Cells Rapidly Modulate Metabolic Pathways Essential for Distinct Effector Functions. J Immunol. 2017 Jan 15;198(2):640-644. doi: 10.4049/jimmunol.1601150. PubMed PMID: 27974455; PMCID: PMC5225044.
Li J, Shayan G, Avery L, Jie HB, Gildener-Leapman N, Schmitt N, Lu BF, Kane LP, Ferris RL. Tumor-infiltrating Tim-3+ T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk. Oncoimmunology. 2016;5(10):e1200778. doi: 10.1080/2162402X.2016.1200778. PubMed PMID: 27853635; PMCID: PMC5087305.
Way EE, Trevejo-Nunez G, Kane LP, Steiner BH, Puri KD, Kolls JK, Chen K. Dose-Dependent Suppression of Cytokine production from T cells by a Novel Phosphoinositide 3-Kinase Delta Inhibitor. Sci Rep. 2016 Jul 27;630384. doi: 10.1038/srep30384. PubMed PMID: 27461849; PMCID: PMC4961957.
Phong B, Kane LP. Mast cell activation is enhanced by Tim1:Tim4 interaction but not by Tim-1 antibodies. F1000Res. 2016;5251. doi: 10.12688/f1000research.8132.2. PubMed PMID: 30023044; PMCID: PMC5584026.
Phong BL, Avery L, Sumpter TL, Gorman JV, Watkins SC, Colgan JD, Kane LP. Tim-3 enhances FcεRI-proximal signaling to modulate mast cell activation. J Exp Med. 2015 Dec 14;212(13):2289-304. doi: 10.1084/jem.20150388. PubMed PMID: 26598760; PMCID: PMC4689164.
Hawse WF, Sheehan RP, Miskov-Zivanov N, Menk AV, Kane LP, Faeder JR, Morel PA. Cutting Edge: Differential Regulation of PTEN by TCR, Akt, and FoxO1 Controls CD4+ T Cell Fate Decisions. J Immunol. 2015 May 15;194(10):4615-9. doi: 10.4049/jimmunol.1402554. PubMed PMID: 25855357; PMCID: PMC4418530.
Kane LP. Antigen receptor kinase two-step. J Immunol. 2014 Nov 1;193(9):4277-8. doi: 10.4049/jimmunol.1402287. PubMed PMID: 25326544.
Ferris RL, Lu B, Kane LP. Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion. J Immunol. 2014 Aug 15;193(4):1525-30. doi: 10.4049/jimmunol.1400557. PubMed PMID: 25086175; PMCID: PMC4120324.
Hamilton KS, Phong B, Corey C, Cheng J, Gorentla B, Zhong X, Shiva S, Kane LP. T cell receptor-dependent activation of mTOR signaling in T cells is mediated by Carma1 and MALT1, but not Bcl10. Sci Signal. 2014 Jun 10;7(329):ra55. doi: 10.1126/scisignal.2005169. PubMed PMID: 24917592; PMCID: PMC4405131.

<< Investigators Search

Top